PriceTargets.com logo

Ergomed - ERGO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 1,525
  • Forecasted Upside: 51.89%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,004 As of 03/24/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ERGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ergomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ERGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ERGO

Analyst Price Target is GBX 1,525
▲ +51.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ergomed in the last 3 months. The average price target is GBX 1,525, with a high forecast of GBX 1,600 and a low forecast of GBX 1,450. The average price target represents a 51.89% upside from the last price of GBX 1,004.

This chart shows the closing price for ERGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Ergomed. This rating has held steady since May 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/21/2023Shore CapitalReiterated RatingHold
3/21/2023Berenberg BankReiterated RatingBuyGBX 1,450
3/7/2023Shore CapitalReiterated RatingBuy
2/14/2023Numis SecuritiesReiterated RatingBuyGBX 1,600
12/8/2022Shore CapitalReiterated RatingHold
9/27/2022Berenberg BankReiterated RatingBuyGBX 1,450
8/4/2022Berenberg BankReiterated RatingBuyGBX 1,450
6/10/2021Shore CapitalReiterated RatingNo Recommendation
5/17/2021Numis SecuritiesUpgradeBuyGBX 1,330 ➝ GBX 1,550
1/26/2021Shore CapitalReiterated RatingNot Rated
6/13/2019Numis SecuritiesReiterated RatingBuy
5/16/2019Numis SecuritiesReiterated RatingBuyGBX 190 ➝ GBX 267
4/10/2019Numis SecuritiesUpgradeBuyGBX 230
9/19/2018Numis SecuritiesUpgradeAddGBX 190
6/28/2018Numis SecuritiesDowngradeHoldGBX 300 ➝ GBX 250
4/11/2018Numis SecuritiesReiterated RatingBuyGBX 300
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Ergomed logo
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Read More

Today's Range

Now: GBX 1,004
Low: 957
High: 1,035

50 Day Range

MA: GBX 1,168.15
Low: 997
High: 1,314

52 Week Range

Now: GBX 1,004
Low: 910
High: 1,478

Volume

65,342 shs

Average Volume

116,455 shs

Market Capitalization

£506.02 million

P/E Ratio

3,861.54

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Ergomed?

The following Wall Street research analysts have issued reports on Ergomed in the last year: Berenberg Bank, Numis Securities Ltd, and Shore Capital.
View the latest analyst ratings for ERGO.

What is the current price target for Ergomed?

2 Wall Street analysts have set twelve-month price targets for Ergomed in the last year. Their average twelve-month price target is GBX 1,525, suggesting a possible upside of 51.9%. Numis Securities Ltd has the highest price target set, predicting ERGO will reach GBX 1,600 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of GBX 1,450 for Ergomed in the next year.
View the latest price targets for ERGO.

What is the current consensus analyst rating for Ergomed?

Ergomed currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ERGO will outperform the market and that investors should add to their positions of Ergomed.
View the latest ratings for ERGO.

What other companies compete with Ergomed?

Other companies that are similar to Ergomed include Silence Therapeutics, PureTech Health, Oxford Biomedica, Horizon Discovery Group plc (HZD.L) and Verona Pharma plc (VRP.L). Learn More about companies similar to Ergomed.

How do I contact Ergomed's investor relations team?

Ergomed's physical mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company's listed phone number is +44-1483-503205. The official website for Ergomed is www.ergomedplc.com. Learn More about contacing Ergomed investor relations.